SPEC-29

SPEC-29 is a novel, uncharged, small-molecule inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3). Discovered through structure-based virtual ligand screening (SB-VLS) of the SPECS database incorporating SH2 domain flexibility, SPEC-29 directly targets the SH2 domain of STAT3, specifically interacting with the pY+0 binding pocket residues R609-S613. By blocking this pocket, SPEC-29 prevents STAT3 phosphorylation (pY-STAT3), dimerization, and downstream transcriptional activity. In preclinical studies, SPEC-29 demonstrated potent inhibition of both cytokine-stimulated and constitutive STAT3 activation, and significantly suppressed the growth of STAT3-dependent breast cancer cell lines, such as MDA-MB-468 and MDA-MB-231. It is being investigated for its potential therapeutic application in cancer, chronic inflammation, and fibrosis.